- Thermo Fisher’s 4Q adjusted earnings per share (EPS) were $6.10, surpassing the estimate of $5.94 and up from $5.67 year-over-year.
- Total revenue for the quarter was $11.40 billion, an increase of 4.7% year-over-year, exceeding the expected $11.29 billion.
- Life sciences revenue reached $2.60 billion, which is a 5.5% rise year-over-year, better than the projected $2.56 billion.
- Revenue from analytical instruments hit $2.19 billion, marking a 7.3% rise year-over-year, surpassing the estimate of $2.12 billion.
- Specialty diagnostics revenue was $1.16 billion, a 4.7% increase year-over-year, slightly missing the expected $1.17 billion.
- Lab products and services revenue grew to $5.94 billion, a gain of 3.8% year-over-year, aligning with the estimate of $5.91 billion.
- Eliminations accounted for a negative $487 million in revenue, a decrease of 9.7% year-over-year.
- Foreign currency impact on sales was 0%, contrasting with 1% last year, and below the estimated 0.6%.
- Adjusted operating income was $2.72 billion, a 6.7% increase year-over-year, slightly above the estimate of $2.68 billion.
- The adjusted operating margin improved to 23.9%, from 23.4% last year, also surpassing the estimated 23.6%.
- The company attributed their success to meaningful market share gains and a strong growth strategy, utilizing their PPI Business System.
- Analysts’ consensus on Thermo Fisher is optimistic, with 27 buy ratings, 4 hold ratings, and no sell ratings.
“`
Thermo Fisher Scientific Inc on Smartkarma
Thermo Fisher Scientific Inc has been receiving positive analyst coverage on Smartkarma, a platform where independent analysts publish their research findings. One notable report was by Baptista Research, titled “Thermo Fisher Scientific: Expansion of Clinical Research & Pharma Services Integration Driving Our Bullishness! – Major Drivers”. The report highlighted the company’s robust financial performance in the third quarter of 2024, amidst a challenging environment. Thermo Fisher Scientific reported impressive figures, including a quarterly revenue of $10.6 billion, an adjusted operating income of $2.36 billion, and an adjusted operating margin of 22.3%. The company’s adjusted earnings per share (EPS) stood at $5.28, emphasizing its ability to consistently deliver value to its shareholders.
A look at Thermo Fisher Scientific Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Thermo Fisher Scientific Inc has a solid long-term outlook based on its Smartkarma Smart Scores. With a balanced score across various factors, including value, growth, resilience, and momentum, the company appears to be positioned well for future success. The company’s strong presence in manufacturing scientific instruments, consumables, and chemicals contributes to its overall positive outlook.
Thermo Fisher Scientific Inc‘s Smartkarma Smart Scores highlight its competitive edge in the industry. While the company may not be the highest scorer in every category, its consistent performance across key factors suggests a stable and promising future ahead. As a manufacturer of analytical instruments, laboratory equipment, and a range of other scientific products, Thermo Fisher Scientific Inc is well-positioned to capitalize on opportunities for growth and innovation in the scientific research and healthcare sectors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
